Figure 1.

Outcome after first cytokine-induced killer (CIK) cell infusion. With the first CIK cell infusion patients were followed for a median of 9.1 months (range 0.9–36.3 months). Three out of 13 patients succumbed to transplant-related complications (TRM) apparently unrelated to CIK cell therapy (9-month CITRM 19.2%, 95%CI: 0.1%–66.4%. (A) Given historically high rates of relapse for this high-risk population within six months, a 9-month follow-up period was chosen for estimates of survival; 9-month probabilities of event-free survival (EFS) and relapse-free survival (RFS) for the 13 patients were estimated to be 61.5% (95%CI: 30.8%–81.8%) and 76.2% (95%Cl: 42.7%–91.7%), respectively (B and C). Four of 13 patients relapsed after transplantation (9-month CIR, 23.8%, 95%CI, 1.1%–63.2%. (D) All of these patients had shown molecular relapse at a median of 3.2 months (range, 2.3–4.1 months) after hematopoietic stem cell transplantation (HSCT). Hematologic relapses occurred at a median of 8.2 months (range 4–17.5 months) after transplantation suggesting that CIK cell treatment may have delayed recurrence of disease.